Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth prior auth & step therapy Policy Updat…
    Ask Trek AI about this page
    CurrentAmeriHealthPolicy N/A

    Formulary utilization management: prior authorization and step therapy for select drugs

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, step therapy, and quantity limits for specific prescription drugs on the AmeriHealth Medicare PPO formulary and describes requirements that affect prescribers and members for new-start and continuing therapy.

    Policy Summary
    PayerAmeriHealth
    PolicyFormulary utilization management: prior authorization and step therapy for select drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewOct 17, 2025
    Next Review DateOct 17, 2025
    Key ActionObtain prior authorization or document required step-therapy trials of specified generic alternatives before the plan will cover listed brand drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multiplelisted with utilization requirements

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ST/PA/QL
    utilization management types described
    manyapplies to new starts
    somealways applies for some

    Coverage Criteria for Formulary Drugs

    Vigafyde (Vigabatrin) trial requirement

    Covered when specified prior trials are met for these products (applies to new starts unless otherwise noted):

    Vigafyde: Trial of Vigpoder or Vigabatrin powder for oral solution requirednew starts

    applies to VIGAFYDE SOLUTION 100 MG/ML ORAL

    Generic trial requirements for antidepressants and antipsychotics

    Covered when specified generic formulary alternatives are tried (applies to new starts):

    Fetzima: Trial of two generic formulary serotonin-norepinephrine reuptake inhibitors (SNRIs) requirednew starts

    applies to FETZIMA strengths and titration pack listed

    Antipsychotics (Rexulti/Sequoado/Vraylar/Fanapt): Trial of two generic formulary antipsychotic products requirednew starts

    applies to listed FANAPT, REXULTI, SECUADO, and VRAYLAR products

    Drizalma (milnacipran) step requirement

    Covered when a specified generic alternative is tried (applies to new starts):

    Drizalma: Trial of generic formulary duloxetine requirednew starts

    applies to DRIZALMA SPRINKLE CAPSULE delayed release 40 mg and 60 mg

    Various product-specific trial requirements

    Covered when specified trials are completed (applies to new starts or always applies as noted):

    Eprontia: Trial of generic formulary immediate‑release pregabalin or topiramate (capsules or solution) requirednew starts

    applies to EPRONTIA SOLUTION 25 MG/ML ORAL

    Basaglar: Trial of two of the following insulin products required: Lantus, Toujeo, Tresibaalways

    Always applies to BASAGLAR KWIKPEN / TEMPO products

    Rebif and MS agents: Trial of two of the following formulary MS disease‑modifying therapies required: Avonex (interferon beta‑1a), Betaseron (interferon beta‑1b), Glatopa (glatiramer acetate), Tecfidera (dimethyl fumarate), Gilenya (fingolimod), Teriflunomidenew starts

    Antiemetic and anticonvulsant step requirements

    Covered when specified anticonvulsant or antiemetic trials are completed (applies to new starts or always applies as noted):

    Sancuso: Trial of (a) ondansetron or granisetron AND (b) aprepitant requiredalways

    applies to SANCUSO PATCH 3.1 MG/24HR; Always applies

    Xcopri: Trial of two generic formulary anticonvulsants requirednew starts

    applies to XCOPRI products and therapy packs listed

    Zonisade step requirement

    Covered when specified generic alternative is tried (applies to new starts):

    Zonisade: Trial of generic zonisamide capsule requirednew starts

    applies to ZONISADE SUSPENSION 100 MG/5ML ORAL

    This document does not list any product-specific clinical exclusions within its coverage criteria section. For information about exclusions that may apply to a particular drug, consult the AmeriHealth Medicare PPO Formulary and the product-specific prior authorization criteria referenced in the plan materials.

    The policy does not enumerate explicit conditions labeled “not medically necessary.” Instead, coverage can be denied when utilization management requirements are not met. In particular, failure to satisfy required Prior Authorization (PA), Step Therapy (ST), or Quantity Limits (QL) listed in this document and the formulary may result in the plan not covering the drug.

    Initial Therapy (New Starts) Requirements

    Initial therapy (new starts)

    Initial therapy (new starts) rules as listed for each product:

    Various products: Most listed products require a trial of specified generic formulary alternatives or specified agents prior to coverage for new startsnew starts

    See product‑specific entries (Vigafyde, Fetzima, antipsychotics, Drizalma, Eprontia, Basaglar, Rebif, Relistor, Sancuso, Xcopri, Zonisade)

    Step Therapy Requirements and Tables

    Product / Affected StrengthsRequired prior trial(s)Applies to
    VIGAFYDE SOLUTION 100 MG/ML ORAL
    Trial of Vigpoder or Vigabatrin powder for oral solution
    Applies to new starts
    FETZIMA CAPSULE ER 20, 40, 80, 120 MG; FETZIMA TITRATION PACK 20 & 40 MG
    Trial of two generic formulary serotonin‑norepinephrine reuptake inhibitors (SNRIs)
    Applies to new starts
    FANAPT (various strengths); REXULTI (various strengths); SECUADO PATCH (3.8/5.7/7.6 MG/24HR); VRAYLAR (1.5,3,4.5,6 MG)
    Trial of two generic formulary antipsychotic products
    Applies to new starts
    DRIZALMA SPRINKLE CAPSULE 40 MG, 60 MG
    Trial of generic formulary duloxetine
    Applies to new starts
    EPRONTIA SOLUTION 25 MG/ML ORAL
    Trial of generic formulary immediate‑release pregabalin or topiramate (capsules or solution)
    Applies to new starts
    BASAGLAR KWIKPEN / TEMPO (100 UNIT/ML)
    Trial of two of the following: Lantus, Toujeo, Tresiba
    Always applies
    REBIF products (various auto‑injectors/syringes/titration packs)
    Trial of two of the following formulary MS disease‑modifying therapies: Avonex, Betaseron, Glatopa, Tecfidera, Gilenya, Teriflunomide
    Applies to new starts
    RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS; RELISTOR TABLET 150 MG ORAL
    Trial of lubiprostone or lactulose
    Always applies
    SANCUSO PATCH 3.1 MG/24HR TRANSDERMAL
    Trial of (a) ondansetron or granisetron AND (b) aprepitant
    Always applies
    SAVELLA (various strengths)
    Trial of generic formulary duloxetine
    Applies to new starts
    XCOPRI (various strengths and therapy packs)
    Trial of two generic formulary anticonvulsants
    Applies to new starts
    ZONISADE SUSPENSION 100 MG/5ML ORAL
    Trial of generic zonisamide capsule
    Applies to new starts

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Our plan requires prior authorization (PA) for certain drugs. You or the prescribing provider must obtain approval from AmeriHealth before the prescription is filled. If prior authorization is not obtained when required, the plan may not cover the drug.

    • See 2025 Utilization Management Criteria: Prior Authorization for the list of drugs requiring PA.
    • Contact the Member Help Team at 1-866-569-5190 (TTY 711) for assistance with PA requirements or documentation.
    • Failure to obtain PA when required may result in denial of coverage at the point of claim.
    Step Therapy

    Step Therapy Required

    Step therapy (ST) is required for multiple listed products. For many drugs, the plan requires trials of one or two specified generic formulary alternatives (e.g., two generic formulary SNRIs for Fetzima, two generic formulary antipsychotics for certain antipsychotic products, two generic formulary anticonvulsants for Xcopri). These step-therapy requirements apply to new starts.

    Definitions

    Prior Authorization (PA)
    DefinitionPrior Authorization (PA): Plan approval required before the prescription is filled; lack of approval may result in the plan not covering the drug.
    Where listedDrugs that require prior authorization are listed in the 2025 Utilization Management Criteria: Prior Authorization and in the plan Formulary.
    Action for providers/membersObtain approval from the plan before dispensing or filling a PA‑required drug; members may request an exception per the Formulary and Evidence of Coverage.
    Support resourcesSee the plan Formulary (List of Covered Drugs) and the 2025 Utilization Management Criteria: Prior Authorization for details; call Member Help Team for assistance.
    Step Therapy (ST)
    DefinitionStep Therapy (ST): Requirement to try specified alternative drugs first for a condition before the plan will cover the requested drug.

    Background and Scope

    This document provides the AmeriHealth Medicare PPO outpatient prescription drug utilization management requirements including Prior Authorization (PA), Step Therapy (ST), and Quantity Limits (QL) for specific formulary drugs. These requirements are intended to be used alongside the plan Formulary and the 2025 Utilization Management Criteria: Prior Authorization to determine coverage for new-start and continuing therapy.

    Policy Summary
    PayerAmeriHealth
    PolicyFormulary utilization management: prior authorization and step therapy for select drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewOct 17, 2025
    Next Review DateOct 17, 2025
    Key ActionObtain prior authorization or document required step-therapy trials of specified generic alternatives before the plan will cover listed brand drugs.
    SourceLink
    On This Page
    Coverage Criteria for Formulary DrugsInitial Therapy (New Starts) RequirementsStep Therapy Requirements and TablesProvider Actions and Authorization RequirementsDefinitionsBackground and Scope

    applies to listed REBIF products

    Relistor: Trial of lubiprostone or lactulose requiredalways

    applies to RELISTOR SOLUTION and TABLET; Always applies

    • Fetzima products: trial of two generic formulary SNRIs. (Applies to new starts.)
    • Antipsychotics (e.g., Rexulti, Vraylar, Secuado): trial of two generic formulary antipsychotic products. (Applies to new starts.)
    • Drizalma: trial of generic formulary duloxetine. (Applies to new starts.)
    • Xcopri: trial of two generic formulary anticonvulsants. (Applies to new starts.)
    Documentation Required

    Documentation and Submission Instructions

    For details about required supporting documentation and where to submit prior authorization requests, consult the plan Formulary and the 2025 Utilization Management Criteria: Prior Authorization, or contact the Member Help Team.

    • Visit www.amerihealthmedicare.com to view the Formulary (List of Covered Drugs) and Utilization Management Criteria.
    • Member Help Team: 1-866-569-5190 (TTY 711), seven days a week from 8 a.m. to 8 p.m.; note possible voicemail routing on weekends/holidays April 1–Sept 30.
    Denial Risk

    Denial Risk if Requirements Not Met

    Not obtaining required prior authorization or failing to meet step-therapy requirements may lead to denial of coverage for the drug.

    • If PA is required and not approved before dispensing, the claim may be denied and the member may be responsible for the cost.
    • Providers may request an exception or submit supporting documentation as described in the Formulary and Evidence of Coverage.
    Where listedDrugs subject to step therapy are identified with 'ST' in the Requirements column of the AmeriHealth Medicare PPO Formulary and detailed in this document.
    Typical requirementCoverage often requires documented trials of one or more generic formulary alternatives (many step therapy rules apply to new starts).
    Action for providers/membersVerify ST requirements in the Formulary index and follow specified trial(s) before requesting coverage; exceptions may be requested per the Formulary and Evidence of Coverage.